Beranda › Limfoma Folikuler › Kentucky › Lexington
Uji klinis Limfoma Folikuler di Lexington, KY
5 studi untuk Limfoma Folikuler mencari peserta di lokasi sekitar Lexington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Menerima pesertaFase 2/3
- University of Kentucky ( Site 1303), Lexington
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Menerima pesertaFase 3
- Research Site, Lexington
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Menerima pesertaFase 1
- University of Kentucky/Markey Cancer Center, Lexington
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Menerima pesertaFase 3
- University of Kentucky, Lexington
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Menerima pesertaFase 3
- Local Institution - 0218, Lexington
Uji klinis Limfoma Folikuler di kota lain
- New York City, NY24 studi
- Milwaukee, WI19 studi
- Nashville, TN18 studi
- Houston, TX18 studi
- Boston, MA17 studi
- Baldwin Park, CA16 studi
- Seattle, WA15 studi
- Durham, NC15 studi
- Salt Lake City, UT13 studi
- Columbus, OH13 studi
- Chicago, IL12 studi
- San Antonio, TX12 studi
Studi lain di Lexington
- Kanker Paru Non-Sel Kecil23 studi
- Kanker Paru18 studi
- Kanker Ovarium16 studi
- Kanker Prostat14 studi
- Kanker (semua jenis)14 studi
- Kanker Payudara14 studi
- Kanker Metastatik11 studi
- Kanker Kolorektal11 studi
- Gagal Jantung11 studi
- Melanoma10 studi
- Leukemia Mieloid Akut10 studi
- Obesitas10 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.